Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects

Conditions:   Prostate Cancer Metastatic Castration-Resistant;   Abnormal DNA Repair;   Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Stage IV Prostate Cancer Interventions:   Drug: Olaparib;   Drug: Abiraterone Acetate;   Drug: Prednisone Sponsors:   Northwestern University;   AstraZeneca;   National Cancer Institute (NCI) Not yet recruiting - verified January 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials